Literature DB >> 29221369

Controversy and perspective in the management of marginally operable stage IIIA non-small cell lung cancer: response to Editorial by Charlotte Billiet and Dirk De Ruysscher and Editorial by Dr. Wanpu Yan and Dr. David R. Jones.

Kai-Lin Yang1,2,3, Jiunn-Song Jiang2,4, Kwan-Hwa Chi1,3.   

Abstract

Entities:  

Year:  2017        PMID： 29221369      PMCID： PMC5708459          DOI： 10.21037/jtd.2017.08.112

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Authors:  Miklos Pless; Roger Stupp; Hans-Beat Ris; Rolf A Stahel; Walter Weder; Sandra Thierstein; Marie-Aline Gerard; Alexandros Xyrafas; Martin Früh; Richard Cathomas; Alfred Zippelius; Arnaud Roth; Milorad Bijelovic; Adrian Ochsenbein; Urs R Meier; Christoph Mamot; Daniel Rauch; Oliver Gautschi; Daniel C Betticher; René-Olivier Mirimanoff; Solange Peters
Journal:  Lancet       Date:  2015-08-11       Impact factor: 79.321

Review 2.  Radiotherapy and immunogenic cell death.

Authors:  Encouse B Golden; Lionel Apetoh
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

3.  Non-small cell lung cancer, version 1.2015.

Authors:  David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Thomas J Dilling; Ramaswamy Govindan; Frederic W Grannis; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Mark G Kris; Lee M Krug; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Steven Schild; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2014-12       Impact factor: 11.908

4.  Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

Authors:  Valerie W Rusch; Dorothy J Giroux; Michael J Kraut; John Crowley; Mark Hazuka; Timothy Winton; David H Johnson; Lawrence Shulman; Frances Shepherd; Claude Deschamps; Robert B Livingston; David Gandara
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

5.  Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.

Authors:  Hiroyasu Yokomise; Masashi Gotoh; Taku Okamoto; Yasumichi Yamamoto; Shinya Ishikawa; Takashi Nakashima; Daiki Masuya; Dage Liu; Cheng-long Huang
Journal:  J Thorac Cardiovasc Surg       Date:  2007-05       Impact factor: 5.209

6.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

7.  Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results.

Authors:  Maya Gottfried; Rodryg Ramlau; Maciej Krzakowski; Grzegorz Ziolo; Henryk Olechnowicz; Leona Koubkova; Jubrail Dahabreh; Aleksandra Szczesna; Guillermo Lopez Vivanco; Reury-Perng Perng; Francesco Carpagnano; Swan-Swan Leong; Alberto Fittipaldo; Cecilia De Almeida; Delphine Aubert; Dominique Grunenwald
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

8.  Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.

Authors:  Kai-Lin Yang; Yih-Chen Chang; Hui-Ling Ko; Mau-Shin Chi; Hsin-Ell Wang; Pei-Sung Hsu; Chen-Chun Lin; Diana Yu-Wung Yeh; Shang-Jyh Kao; Jiunn-Song Jiang; Kwan-Hwa Chi
Journal:  Clin Lung Cancer       Date:  2016-06-08       Impact factor: 4.785
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.